Bausch Health Companies’ (BHC) “Sector Perform” Rating Reiterated at Royal Bank of Canada

Royal Bank of Canada restated their sector perform rating on shares of Bausch Health Companies (NYSE:BHCFree Report) in a report issued on Friday, Benzinga reports. Royal Bank of Canada currently has a $12.00 price target on the stock.

Several other research firms have also recently issued reports on BHC. StockNews.com raised shares of Bausch Health Companies from a hold rating to a buy rating in a research report on Wednesday, February 7th. Jefferies Financial Group decreased their target price on shares of Bausch Health Companies from $16.00 to $14.00 and set a buy rating on the stock in a research report on Tuesday, February 20th.

Get Our Latest Stock Analysis on Bausch Health Companies

Bausch Health Companies Price Performance

Bausch Health Companies stock opened at $8.76 on Friday. Bausch Health Companies has a 12-month low of $5.57 and a 12-month high of $11.46. The stock has a market capitalization of $3.20 billion, a P/E ratio of -5.41 and a beta of 0.85. The firm’s 50-day moving average is $9.23 and its two-hundred day moving average is $8.14.

Bausch Health Companies (NYSE:BHCGet Free Report) last released its earnings results on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.01 by $0.14. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The business had revenue of $2.41 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period last year, the company earned $1.02 earnings per share. The company’s quarterly revenue was up 9.8% on a year-over-year basis. As a group, analysts forecast that Bausch Health Companies will post 3.95 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the business. Salem Investment Counselors Inc. purchased a new stake in shares of Bausch Health Companies during the first quarter valued at approximately $32,000. Principal Securities Inc. purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $31,000. Lazard Asset Management LLC purchased a new stake in shares of Bausch Health Companies during the second quarter valued at approximately $49,000. Tower Research Capital LLC TRC raised its stake in shares of Bausch Health Companies by 283.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,918 shares of the company’s stock valued at $55,000 after purchasing an additional 5,112 shares during the period. Finally, Bfsg LLC purchased a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $63,000. Hedge funds and other institutional investors own 78.65% of the company’s stock.

Bausch Health Companies Company Profile

(Get Free Report)

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.

Read More

Receive News & Ratings for Bausch Health Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bausch Health Companies and related companies with MarketBeat.com's FREE daily email newsletter.